By Lina carolina 
Basal cell carcinomas (BCCs), the most prevalent form of skin cancer, typically manifest in areas of the skin subjected to chronic sun exposure, with the face being a common site. For locally advanced BCCs, surgical intervention often presents significant challenges, potentially leading to functional impairments and considerable cosmetic alterations. In a groundbreaking development, a collaborative research initiative involving MedUni Vienna and University Hospital Vienna has unveiled promising results from a clinical study investigating a novel therapeutic approach. The study, published in the esteemed journal Nature Cancer, highlights the remarkable efficacy of Talimogene Laherparepvec (TVEC), an oncolytic immunotherapy, in reducing tumour size, facilitating less invasive surgical procedures, and in some instances, achieving complete tumour regression in patients with locally advanced BCCs.
The Promise of Oncolytic Immunotherapy in BCC Treatment
The research team focused on TVEC, a genetically engineered herpes simplex virus (HSV) that has previously received regulatory approval for the treatment of superficial melanoma metastases. The mechanism of action for TVEC is twofold: it directly targets and destroys cancer cells while simultaneously stimulating the body’s immune system to recognize and attack the malignant cells. The primary objective of this study was to assess TVEC’s potential as a neoadjuvant therapy – a treatment administered prior to surgery – with the aim of shrinking tumours to a size that would allow for simpler surgical removal, thereby minimizing the risk of post-operative functional limitations and disfiguring cosmetic outcomes.
The clinical trial enrolled 18 patients diagnosed with locally advanced BCCs. These individuals were candidates for significant reconstructive surgery, such as flap or skin graft procedures, due to the size and specific location of their tumours. Over a period of 13 weeks, each participant received a series of six intralesional injections of TVEC directly into the tumour site. This pre-operative treatment regimen was designed to induce tumour shrinkage and an anti-tumour immune response before the planned surgical excision.
Significant Tumour Reduction and Favourable Surgical Outcomes
The findings from this pioneering study are highly encouraging. According to the principal investigator, Christoph Höller, Head of the Skin Tumour Centre at the Department of Dermatology, the treatment achieved substantial tumour reduction in a significant proportion of the study participants. "This enabled the tumour to be reduced in size in half of the patients to such an extent that surgery with direct wound closure was possible," stated Dr. Höller. This outcome is particularly noteworthy as it suggests that TVEC can effectively downstage tumours, transforming complex surgical cases into those amenable to less invasive techniques, thereby preserving healthy tissue and improving aesthetic results.
Furthermore, the therapeutic impact of TVEC extended beyond mere size reduction. In a substantial subset of patients, subsequent histological examinations of the surgically removed tumours revealed the absence of viable tumour cells. "In a third of the cases, the subsequent histological examination even showed no more living tumour cells," Dr. Hèller elaborated. This indicates a potential for complete eradication of the tumour through the combined effect of TVEC-induced cell death and immune-mediated destruction. Crucially, no patient in the study experienced tumour progression during the TVEC treatment period. "All treated tumours at least became smaller, and no tumour grew further under the therapy. The treatment was well tolerated by the patients," he added, underscoring the safety profile of the new therapeutic approach.
Julia Ressler, the first author of the study and a researcher from the Department of Dermatology, emphasized the clinical implications of these findings. "The new treatment option for basal cell carcinoma can not only simplify surgery, but also help to avoid disfiguring operations and functional limitations," she remarked. This sentiment highlights the profound impact TVEC could have on the quality of life for patients undergoing treatment for advanced skin cancers, offering hope for improved functional outcomes and a better cosmetic appearance post-surgery.
Immune System Activation: A Deeper Understanding
Beyond the direct clinical observations, the research team conducted comprehensive analyses to elucidate the immunological mechanisms underlying TVEC’s effectiveness. In collaboration with the St. Anna Children’s Hospital, researchers performed detailed investigations into the tumour microenvironment. These analyses provided compelling evidence that TVEC therapy significantly enhances the immune defence within the tumour tissue. This activation of the immune system is a critical component of oncolytic virotherapy, as it not only leads to direct tumour cell lysis but also primes the immune system to mount a more robust and sustained anti-tumour response. The observed strengthening of immune defence suggests that TVEC may not only shrink tumours but also contribute to long-term immune surveillance, potentially reducing the risk of recurrence.
Implications for Future Treatment Strategies and Broader Impact
The study’s findings position TVEC as a highly promising neoadjuvant treatment option for basal cell carcinoma, particularly for patients where extensive surgical interventions pose significant risks or are likely to result in substantial functional and cosmetic compromises. The ability to reduce tumour burden and improve surgical candidacy before the operation represents a paradigm shift in the management of advanced BCCs.
The publication in Nature Cancer, a journal renowned for its rigorous peer-review process and high impact, signifies the scientific community’s recognition of the importance and potential of this research. This validation lends significant weight to the study’s conclusions and is likely to spur further investigation into TVEC’s role in oncology.
The researchers are optimistic about the future of this therapy and plan to conduct further studies. "Further studies are to follow in order to confirm the benefits of this new option in a larger patient population," stated Dr. Höller, indicating a commitment to solidifying these promising results. Expanding the clinical trial to include a larger and more diverse patient cohort will be crucial in confirming TVEC’s efficacy and safety across a broader spectrum of BCC presentations and patient profiles. Such studies will also be instrumental in determining optimal dosing regimens, treatment durations, and identifying patient subgroups most likely to benefit from this innovative approach.
Context and Background: The Challenge of Locally Advanced BCC
Basal cell carcinoma, accounting for approximately 80% of all non-melanoma skin cancers, arises from the basal cells of the epidermis. While generally slow-growing and rarely metastasizing, BCCs can become locally aggressive, invading surrounding tissues, including cartilage, bone, and nerves, especially when left untreated or when they occur in specific anatomical locations like the central face, eyelids, or ears. These locally advanced tumours present a significant therapeutic challenge. Traditional treatments include surgical excision, Mohs surgery (a specialized technique offering precise tumour removal with maximal tissue preservation), curettage and electrodesiccation, cryotherapy, and radiation therapy. However, for tumours that are large, deeply invasive, or located in aesthetically sensitive areas, these modalities may not be sufficient or may lead to significant functional and cosmetic deficits. Reconstructive surgery, often involving skin grafts or tissue flaps, becomes necessary, increasing morbidity and recovery time.
The development of systemic therapies for BCC has historically been limited, with targeted therapies and immunotherapies primarily reserved for advanced or metastatic cases. The introduction of an effective neoadjuvant therapy that can shrink tumours prior to definitive treatment holds immense potential to revolutionize the management of locally advanced BCCs, offering a less burdensome and more aesthetically favourable pathway to remission.
Timeline of Development and Future Directions
The journey from identifying the potential of oncolytic viruses to their application in clinical settings is a testament to decades of scientific research. The development of TVEC itself has been a gradual process, building upon fundamental understanding of virology and immunology. The initial approval of TVEC for melanoma marked a significant milestone, paving the way for its exploration in other cancer types.
The current study represents a crucial step in this ongoing evolution. The timeline of this specific clinical trial likely involved several phases:
- Pre-clinical Research: Laboratory studies and animal models to assess TVEC’s safety and efficacy against BCC cells.
- Phase I/II Clinical Trials: The current study, likely a Phase II trial, focused on evaluating the efficacy and safety of TVEC in a targeted patient population.
- Publication and Dissemination: The reporting of findings in a high-impact journal like Nature Cancer signifies the culmination of this research phase.
- Future Clinical Trials (Phase III): The planned larger-scale studies to confirm efficacy, compare TVEC with existing standards of care, and further refine treatment protocols.
- Regulatory Approval: If future trials are successful, the pathway towards seeking regulatory approval for TVEC in BCC treatment would be initiated.
The broader implications of this research extend beyond BCC. The success of TVEC in stimulating an anti-tumour immune response within the tumour microenvironment suggests that this therapeutic strategy could be applicable to other solid tumours that are currently challenging to treat surgically or with existing systemic therapies. Further research could explore the combination of TVEC with other immunotherapies or conventional treatments to enhance synergistic effects and overcome treatment resistance.
The collaborative spirit evident in this research, involving multiple departments and institutions, underscores the importance of interdisciplinary approaches in tackling complex medical challenges. The continued dedication of researchers like Dr. Höller and Dr. Ressler, coupled with the investment in further clinical investigation, holds the promise of transforming the treatment landscape for patients suffering from basal cell carcinoma and potentially other forms of cancer.